|
08-2025
|
NICHD International and Domestic Pediatric and Maternal HIV and Other High Priority Infectious Diseases Data Coordinating Center
NICHD International and Domestic Pediatric and Maternal HIV and Other High Priority Infectious Diseases Data Coordinating Center
|
|
08-2025
|
NICHD International and Domestic Pediatric and Maternal HIV and Other High Priority Infectious Diseases Data Coordinating Center
NICHD International and Domestic Pediatric and Maternal HIV and Other High Priority Infectious Diseases Data Coordinating Center
|
|
11-2024
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636]
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636]
|
|
02-2024
|
Health Outcomes around Pregnancy and Exposure to HIV/ARVs (HOPE) - Extending the Reach of PHACS to Examine Women's Health
Health Outcomes around Pregnancy and Exposure to HIV/ARVs (HOPE) - Extending the Reach of PHACS to Examine Women's Health
|
|
12-2023
|
FLORIDA DEPARTMENT OF HEALTH-DUVAL COUNTY ENDING THE HIV EPIDEMIC COMMUNITY FUNDING
FLORIDA DEPARTMENT OF HEALTH-DUVAL COUNTY ENDING THE HIV EPIDEMIC COMMUNITY FUNDING
|
|
11-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 AstraZeneca
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 AstraZeneca
|
|
10-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 Synairgen
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 Synairgen
|
|
10-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 BMS
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 BMS
|
|
10-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 Sagent Camostat
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401 Sagent Camostat
|
|
10-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401-SAB185
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401-SAB185
|
|
07-2023
|
Exploratory Study of Linguistic Biases within the CELF-4 for Children HIV Exposed but Uninfected (CHEU) in the SMARTT Cohort, Ages 5 and 9 Years
Exploratory Study of Linguistic Biases within the CELF-4 for Children HIV Exposed but Uninfected (CHEU) in the SMARTT Cohort, Ages 5 and 9 Years
|
|
07-2023
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
07-2023
|
Pediatric HIV/AIDS Cohort Study (PHACS) Maternal Mental Health
Pediatric HIV/AIDS Cohort Study (PHACS) Maternal Mental Health
|
|
07-2023
|
Pediatric HIV/AIDS Cohort Study (PHACS):2022, Y3 SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS):2022, Y3 SMARTT
|
|
07-2023
|
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POPS)
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POPS)
|
|
07-2023
|
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POPS)
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POPS)
|
|
06-2023
|
Pediatric Trial Network eSource Study Selection
Pediatric Trial Network eSource Study Selection
|
|
04-2023
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
|
|
02-2023
|
Ryan White HIV/AIDS Program Part A Services
Ryan White HIV/AIDS Program Part A Services
|
|
09-2022
|
Technology Based Community Health Nursing to Improve cART Adherence and Virologic Suppression in Youth Living with HIV (TechN 2 CheckIN): A Regional Multi-site Study
Technology Based Community Health Nursing to Improve cART Adherence and Virologic Suppression in Youth Living with HIV (TechN 2 CheckIN): A Regional Multi-site Study
|
|
09-2022
|
Technology Based Community Health Nursing to Improve cART Adherence and Virologic Suppression in Youth Living with HIV (TechN 2 CheckIN): A Regional Multi-site Study
Technology Based Community Health Nursing to Improve cART Adherence and Virologic Suppression in Youth Living with HIV (TechN 2 CheckIN): A Regional Multi-site Study
|
|
07-2022
|
Pediatric HIV/AIDS Cohort Study (PHACS) AMP Up Lite
Pediatric HIV/AIDS Cohort Study (PHACS) AMP Up Lite
|
|
07-2022
|
Pediatric HIV/AIDS Cohort Study (PHACS):2021, SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS):2021, SMARTT
|
|
07-2022
|
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
|
|
07-2022
|
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
|
|
07-2022
|
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
|
|
05-2022
|
Strategic Timing of Antiretroviral Therapy (START) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT 101)
Strategic Timing of Antiretroviral Therapy (START) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT 101)
|
|
04-2022
|
Part C: Ryan White Title III Outpatient EIS Program
Part C: Ryan White Title III Outpatient EIS Program
|
|
03-2022
|
CoVPN 3006 Protocol Funding (PF) - Jacksonville Protocol-Specific Site
CoVPN 3006 Protocol Funding (PF) - Jacksonville Protocol-Specific Site
|
|
03-2022
|
COVID-19 Prevention Network (CoVPN) Site Preparedness Funding - Jacksonville, FL
COVID-19 Prevention Network (CoVPN) Site Preparedness Funding - Jacksonville, FL
|
|
03-2022
|
COVID-19 Prevention Network (CoVPN) Site Preparedness Funding - Jacksonville, FL
COVID-19 Prevention Network (CoVPN) Site Preparedness Funding - Jacksonville, FL
|
|
02-2022
|
Ryan White Part A 2021-2022
Ryan White Part A 2021-2022
|
|
01-2022
|
Baker County Health Department 21-22 - HIV Specialty Services
Baker County Health Department 21-22 - HIV Specialty Services
|
|
12-2021
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG)
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG)
|
|
11-2021
|
COVID-19 Prevention Network (CoVPN) - Fred Hutch Ops Center## CoVPN Trials Site Preparedness Budget 3006##
COVID-19 Prevention Network (CoVPN) - Fred Hutch Ops Center## CoVPN Trials Site Preparedness Budget 3006##
|
|
11-2021
|
LOC-IMPAACT Leadership Group Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
LOC-IMPAACT Leadership Group Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
|
|
11-2021
|
IMPAACT Leadership Group-Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
IMPAACT Leadership Group-Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
|
|
11-2021
|
IMPAACT Leadership Group-Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
IMPAACT Leadership Group-Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
|
|
08-2021
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
|
|
08-2021
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) no. ACTIV-2/A5401
|
|
07-2021
|
Pediatric HIV/AIDS Cohort Study (PHACS) 2020 AMP Up Series
Pediatric HIV/AIDS Cohort Study (PHACS) 2020 AMP Up Series
|
|
07-2021
|
Pediatric HIV/AIDS Cohort Study (PHACS):2020,SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS):2020,SMARTT
|
|
06-2021
|
Baker County Health Department 20-21
Baker County Health Department 20-21
|
|
06-2021
|
Baker County Health Department 20-21
Baker County Health Department 20-21
|
|
03-2021
|
Part A UF Cares 2020 COVID Telemedicine
Part A UF Cares 2020 COVID Telemedicine
|
|
03-2021
|
Part A UF Cares 2020 COVID Telemedicine
Part A UF Cares 2020 COVID Telemedicine
|
|
03-2021
|
Ryan White HIV/AIDS Program Part C EIS COVID19 Response
Ryan White HIV/AIDS Program Part C EIS COVID19 Response
|
|
03-2021
|
Ryan White HIV/AIDS Program Part D WICY COVID19 Response
Ryan White HIV/AIDS Program Part D WICY COVID19 Response
|
|
02-2021
|
Ryan White Part A 2020-2021
Ryan White Part A 2020-2021
|
|
02-2021
|
Ryan White Part A 2020-2021
Ryan White Part A 2020-2021
|
|
01-2021
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
|
|
01-2021
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
|
|
12-2020
|
Adolescent Master Protocol for Participants 18 Years of Age and Older - Lite (AMP Up Lite)
Adolescent Master Protocol for Participants 18 Years of Age and Older - Lite (AMP Up Lite)
|
|
12-2020
|
Adolescent Master Protocol for Participants 18 Years of Age and Older - Lite (AMP Up Lite)
Adolescent Master Protocol for Participants 18 Years of Age and Older - Lite (AMP Up Lite)
|
|
12-2020
|
Targeted Outreach for Pregnant Women Act (TOPWA)
Targeted Outreach for Pregnant Women Act (TOPWA)
|
|
12-2020
|
Targeted Outreach for Pregnant Women Act (TOPWA)
Targeted Outreach for Pregnant Women Act (TOPWA)
|
|
11-2020
|
IMPAACT PSTO PTCL 05 UFlorida 5051 Rathore Y14 PF Supplement
IMPAACT PSTO PTCL 05 UFlorida 5051 Rathore Y14 PF Supplement
|
|
11-2020
|
IMPAACT PSTO PTCL 05 UFlorida 5051 Rathore Y14 PF Supplement
IMPAACT PSTO PTCL 05 UFlorida 5051 Rathore Y14 PF Supplement
|
|
11-2020
|
2018 ACTG (AIDS Clinical Trials Group) Personnel Funds # UCLA
2018 ACTG (AIDS Clinical Trials Group) Personnel Funds # UCLA
|
|
11-2020
|
2018 ACTG (AIDS Clinical Trials Group) Personnel Funds # UCLA
2018 ACTG (AIDS Clinical Trials Group) Personnel Funds # UCLA
|
|
11-2020
|
2018 ACTG (AIDS Clinical Trials Group) Protocol Funds # UCLA
2018 ACTG (AIDS Clinical Trials Group) Protocol Funds # UCLA
|
|
11-2020
|
2018 ACTG (AIDS Clinical Trials Group) Protocol Funds # UCLA
2018 ACTG (AIDS Clinical Trials Group) Protocol Funds # UCLA
|
|
10-2020
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 3502 Protocol F
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 3502 Protocol F
|
|
09-2020
|
IMPAACT PSTO PTCL 02 MOD 01 PF Other Y14 U Florida 5051 Rathore Bridge Funding due to COVID19
IMPAACT PSTO PTCL 02 MOD 01 PF Other Y14 U Florida 5051 Rathore Bridge Funding due to COVID19
|
|
09-2020
|
IMPAACT PSTO PTCL 02 MOD 01 PF Other Y14 U Florida 5051 Rathore Bridge Funding due to COVID19
IMPAACT PSTO PTCL 02 MOD 01 PF Other Y14 U Florida 5051 Rathore Bridge Funding due to COVID19
|
|
06-2020
|
Baker County Health Department 19-20
Baker County Health Department 19-20
|
|
06-2020
|
Baker County Health Department 19-20
Baker County Health Department 19-20
|
|
05-2020
|
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
|
|
05-2020
|
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
|
|
02-2020
|
Ryan White Part A 2019-2020
Ryan White Part A 2019-2020
|
|
02-2020
|
Ryan White Part A 2019-2020
Ryan White Part A 2019-2020
|
|
12-2019
|
CMS Employee Interchange Agreement, Dr. Rathore, CMS Medical Director, COQYW
CMS Employee Interchange Agreement, Dr. Rathore, CMS Medical Director, COQYW
|
|
07-2019
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
07-2019
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
07-2019
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
07-2019
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
06-2019
|
Baker County Health Department HIV Specialty services
Baker County Health Department HIV Specialty services
|
|
06-2019
|
Baker County Health Department HIV Specialty services
Baker County Health Department HIV Specialty services
|
|
06-2019
|
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 27
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 27
|
|
06-2019
|
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 27
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 27
|
|
05-2019
|
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
|
|
05-2019
|
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
|
|
05-2019
|
Strategic Timing of Antiretroviral Therapy (START) or International Network for Strategic Initiatives in Global HIV Trials (INSIGHT I01)
Strategic Timing of Antiretroviral Therapy (START) or International Network for Strategic Initiatives in Global HIV Trials (INSIGHT I01)
|
|
02-2019
|
Ryan White Part A 2017-18
Ryan White Part A 2017-18
|
|
02-2019
|
Ryan White Part A 2017-18
Ryan White Part A 2017-18
|
|
12-2018
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
12-2018
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
11-2018
|
LOC-IMPAACT Leadership Group- PTCL-02 Start-up fees 2014
LOC-IMPAACT Leadership Group- PTCL-02 Start-up fees 2014
|
|
11-2018
|
LOC-IMPAACT Leadership Group- PTCL-02 Start-up fees 2014
LOC-IMPAACT Leadership Group- PTCL-02 Start-up fees 2014
|
|
11-2018
|
LOC-IMPAACT Leadership Group-2017
LOC-IMPAACT Leadership Group-2017
|
|
11-2018
|
LOC-IMPAACT Leadership Group-2017
LOC-IMPAACT Leadership Group-2017
|
|
11-2018
|
Impaact Core Funding for Site 5051
Impaact Core Funding for Site 5051
|
|
11-2018
|
Impaact Core Funding for Site 5051
Impaact Core Funding for Site 5051
|
|
07-2018
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
07-2018
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC)
|
|
06-2018
|
HIV Reengagement in Care DCHD
HIV Reengagement in Care DCHD
|
|
06-2018
|
HIV Reengagement in Care DCHD
HIV Reengagement in Care DCHD
|
|
06-2018
|
Baker County Health Dept-Ryan White Program
Baker County Health Dept-Ryan White Program
|
|
06-2018
|
Baker County Health Dept-Ryan White Program
Baker County Health Dept-Ryan White Program
|
|
06-2018
|
Identification of potent neutralizing Zika virus antibodies using single-cell analysis technology
Identification of potent neutralizing Zika virus antibodies using single-cell analysis technology
|
|
05-2018
|
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Coordinating Center
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Coordinating Center
|
|
05-2018
|
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Coordinating Center
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Coordinating Center
|
|
04-2018
|
HIV Early Intervention Services Existing Geographic Service Areas (Part C)
HIV Early Intervention Services Existing Geographic Service Areas (Part C)
|
|
03-2018
|
Expanded Testing Initiative
Expanded Testing Initiative
|
|
03-2018
|
Expanded Testing Initiative
Expanded Testing Initiative
|
|
02-2018
|
Ryan white Part A 2017-18
Ryan white Part A 2017-18
|
|
02-2018
|
Ryan white Part A 2017-18
Ryan white Part A 2017-18
|
|
12-2017
|
CMS Medical Director 2015-2017
CMS Medical Director 2015-2017
|
|
11-2017
|
Subcontract Under NICHD Prime Contract No. HHSN275201300003C, NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center, Westat ID-6101-S038.
Subcontract Under NICHD Prime Contract No. HHSN275201300003C, NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center, Westat ID-6101-S038.
|
|
11-2017
|
Subcontract Under NICHD Prime Contract No. HHSN275201300003C, NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center, Westat ID-6101-S038.
Subcontract Under NICHD Prime Contract No. HHSN275201300003C, NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center, Westat ID-6101-S038.
|
|
08-2017
|
Partnership for Access to Treatment and Housing (PATH Home) HIV Homeless SPNS
Partnership for Access to Treatment and Housing (PATH Home) HIV Homeless SPNS
|
|
07-2017
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
|
|
07-2017
|
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC):SMARTT
|
|
07-2017
|
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare.
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare.
|
|
06-2017
|
Baker County Health Department - HIV Specialty Services 2015- 2016
Baker County Health Department - HIV Specialty Services 2015- 2016
|
|
02-2017
|
RYAN WHITE PART A 2016-17
RYAN WHITE PART A 2016-17
|
|
02-2017
|
RYAN WHITE PART A 2016-17
RYAN WHITE PART A 2016-17
|
|
12-2016
|
The Effects of Racial Discrim, Soc., Sup., and Exec. Func. on HIV Heatlh Outcomes
The Effects of Racial Discrim, Soc., Sup., and Exec. Func. on HIV Heatlh Outcomes
|
|
12-2016
|
The Effects of Racial Discrim, Soc., Sup., and Exec. Func. on HIV Heatlh Outcomes
The Effects of Racial Discrim, Soc., Sup., and Exec. Func. on HIV Heatlh Outcomes
|
|
12-2016
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
12-2016
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
11-2016
|
A phase I open label multi center study to determine the pharmacokinetics and safety of solithromycin as add on therapy in adolescents and children with suspected or confirmed bacterial infection
A phase I open label multi center study to determine the pharmacokinetics and safety of solithromycin as add on therapy in adolescents and children with suspected or confirmed bacterial infection
|
|
11-2016
|
A phase I open label multi center study to determine the pharmacokinetics and safety of solithromycin as add on therapy in adolescents and children with suspected or confirmed bacterial infection
A phase I open label multi center study to determine the pharmacokinetics and safety of solithromycin as add on therapy in adolescents and children with suspected or confirmed bacterial infection
|
|
08-2016
|
Clinical and Translational Science Institute
Clinical and Translational Science Institute
|
|
07-2016
|
Pediatrics HIV/AIDS Cohort Study (PHACS); Surveillance Monitoring for ART Toxicities in HIV uninfected children born to HIV infected women (SMARTT study)
Pediatrics HIV/AIDS Cohort Study (PHACS); Surveillance Monitoring for ART Toxicities in HIV uninfected children born to HIV infected women (SMARTT study)
|
|
07-2016
|
Pediatrics HIV/AIDS Cohort Study (PHACS); Surveillance Monitoring for ART Toxicities in HIV uninfected children born to HIV infected women (SMARTT study)
Pediatrics HIV/AIDS Cohort Study (PHACS); Surveillance Monitoring for ART Toxicities in HIV uninfected children born to HIV infected women (SMARTT study)
|
|
06-2016
|
TARGETED OUTREACH FOR PREGNANT WOMEN ACT (TOPWA) - UF CARES ,- PEDS ID ,
TARGETED OUTREACH FOR PREGNANT WOMEN ACT (TOPWA) - UF CARES ,- PEDS ID ,
|
|
06-2016
|
TARGETED OUTREACH FOR PREGNANT WOMEN ACT (TOPWA) - UF CARES ,- PEDS ID ,
TARGETED OUTREACH FOR PREGNANT WOMEN ACT (TOPWA) - UF CARES ,- PEDS ID ,
|
|
06-2016
|
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 20
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 20
|
|
06-2016
|
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 20
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care, Task Order No. 20
|
|
02-2016
|
City of Jacksonville Ryan White Part A/MAI FY 2015-2016
City of Jacksonville Ryan White Part A/MAI FY 2015-2016
|
|
02-2016
|
City of Jacksonville Ryan White Part A/MAI FY 2015-2016
City of Jacksonville Ryan White Part A/MAI FY 2015-2016
|
|
08-2015
|
UF CARES Adolescent/Youth Support Group
UF CARES Adolescent/Youth Support Group
|
|
07-2015
|
A PHASE 1, OPEN-LABEL, MULTI-CENTER STUDY TO DETERMINE T
A PHASE 1, OPEN-LABEL, MULTI-CENTER STUDY TO DETERMINE T
|
|
07-2015
|
PHACS:SMARTT
PHACS:SMARTT
|
|
06-2015
|
HIV Specialty Healthcare for Baker County Health Dept
HIV Specialty Healthcare for Baker County Health Dept
|
|
06-2015
|
TOPWA UF Cares - Peds ID
TOPWA UF Cares - Peds ID
|
|
03-2015
|
HBV Early Identification and Linkage to Care
HBV Early Identification and Linkage to Care
|
|
02-2015
|
City of Jacksonville Ryan White Part A/MAI
City of Jacksonville Ryan White Part A/MAI
|
|
08-2014
|
PTN-POPS Task #6
PTN-POPS Task #6
|
|
07-2014
|
PHACS: SMARTT
PHACS: SMARTT
|
|
06-2014
|
HIV Specialty Healthcare for Baker County Health Dept.
HIV Specialty Healthcare for Baker County Health Dept.
|
|
06-2014
|
TOPWA UF Cares - Peds ID
TOPWA UF Cares - Peds ID
|
|
06-2014
|
Ryan White Part C
Ryan White Part C
|
|
06-2014
|
AETC Jacksonville- UF CARES/Rainbow Center
AETC Jacksonville- UF CARES/Rainbow Center
|
|
02-2014
|
City of Jacksonville Ryan White Part A/MAI
City of Jacksonville Ryan White Part A/MAI
|
|
12-2013
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
09-2013
|
HIP for Men
HIP for Men
|
|
07-2013
|
PHACS 2012-13
PHACS 2012-13
|
|
06-2013
|
HIV Specialty HealthCare for Baker County Health Dept
HIV Specialty HealthCare for Baker County Health Dept
|
|
02-2013
|
City of Jacksonville Ryan White Part A/MAI
City of Jacksonville Ryan White Part A/MAI
|
|
11-2012
|
IMPAACT
IMPAACT
|
|
09-2012
|
Expanded Testing Initiative (ETI)
Expanded Testing Initiative (ETI)
|
|
07-2012
|
Pediatrics HIV/AIDS Cohort study (PHACS) Patient Care
Pediatrics HIV/AIDS Cohort study (PHACS) Patient Care
|
|
07-2012
|
Ryan White Tittle IV Program Part D
Ryan White Tittle IV Program Part D
|
|
06-2012
|
Baker County Health Department - Monthly HIV Specialty S
Baker County Health Department - Monthly HIV Specialty S
|
|
06-2012
|
TOPWA: UF Cares, Peds ID
TOPWA: UF Cares, Peds ID
|
|
06-2012
|
Pharmacotherapy to reduce hazardous drinking in HIV-infe
Pharmacotherapy to reduce hazardous drinking in HIV-infe
|
|
02-2012
|
City of Jacksonville Ryan White Part A/MAI
City of Jacksonville Ryan White Part A/MAI
|
|
12-2011
|
Northeastern Early Steps
Northeastern Early Steps
|
|
09-2011
|
Expanded Testing Initiative
Expanded Testing Initiative
|
|
07-2011
|
Pediatric HIV/AIDS Cohort Study (PHACS) Patient Care
Pediatric HIV/AIDS Cohort Study (PHACS) Patient Care
|
|
07-2011
|
Ryan White Title IV Program Part D
Ryan White Title IV Program Part D
|
|
06-2011
|
Baker County Health Department Monthly HIV Clinic.
Baker County Health Department Monthly HIV Clinic.
|
|
06-2011
|
TOPWA: UF Cares, Peds ID
TOPWA: UF Cares, Peds ID
|
|
06-2011
|
CMS:Early Steps
CMS:Early Steps
|
|
06-2011
|
Part C Early Intervention Services Grant
Part C Early Intervention Services Grant
|
|
06-2011
|
HIV/FIV Cat Model: A Model to Identify Vaccine Epitopes
HIV/FIV Cat Model: A Model to Identify Vaccine Epitopes
|
|
03-2011
|
Daytona Treatment Adherence
Daytona Treatment Adherence
|
|
02-2011
|
Shands Medical Case Management Program
Shands Medical Case Management Program
|
|
02-2011
|
City of Jacksonville Ryan White Part A/MAI
City of Jacksonville Ryan White Part A/MAI
|
|
11-2010
|
IMPAACT: Protocol 1086
IMPAACT: Protocol 1086
|
|
11-2010
|
IMPAACT: Protocol 1088
IMPAACT: Protocol 1088
|
|
09-2010
|
AATI-DOH
AATI-DOH
|
|
07-2010
|
FY 09-10 MAI
FY 09-10 MAI
|
|
07-2010
|
Part D Rainbow Center 2009-10 Rathore
Part D Rainbow Center 2009-10 Rathore
|
|
07-2010
|
PHACS
PHACS
|
|
02-2010
|
Ryan White Part A
Ryan White Part A
|
|
11-2009
|
Gilead: GS-US-104-0352
Gilead: GS-US-104-0352
|
|
08-2009
|
Ryan White Part C HIV Capacity Development and Planning
Ryan White Part C HIV Capacity Development and Planning
|
|
07-2009
|
Part D Rainbow Center 2008
Part D Rainbow Center 2008
|
|
07-2009
|
PHACS: SMARTT
PHACS: SMARTT
|
|
06-2009
|
RW Part C 2007
RW Part C 2007
|
|
05-2009
|
Allergan
Allergan
|
|
12-2008
|
Gilead Protocol 104-0321
Gilead Protocol 104-0321
|
|
11-2008
|
A Prospective Open-label Non-randomized, Naturalistic
A Prospective Open-label Non-randomized, Naturalistic
|
|
10-2008
|
Medimmune MI-CP-150
Medimmune MI-CP-150
|
|
07-2008
|
Ryan White Part D- Rathore Jax - Peds ID
Ryan White Part D- Rathore Jax - Peds ID
|
|
07-2008
|
SMARTT
SMARTT
|
|
04-2008
|
Longitudinal Epidemiologic Study to Gain Insight into HI
Longitudinal Epidemiologic Study to Gain Insight into HI
|
|
02-2008
|
Aventis - Otitis Media
Aventis - Otitis Media
|
|
12-2007
|
AIDS CLINICAL TRIALS
AIDS CLINICAL TRIALS
|
|
10-2007
|
P1021 - OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERAN
P1021 - OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERAN
|
|
07-2007
|
PHACS
PHACS
|
|
07-2007
|
PHACS SMARTT
PHACS SMARTT
|
|
07-2007
|
Ryan White Title IV
Ryan White Title IV
|
|
07-2007
|
6096A1/Phase I/II
6096A1/Phase I/II
|
|
06-2007
|
RW Title III EIS 2006
RW Title III EIS 2006
|
|
12-2006
|
Lofbo-ltss-001...Active Surveillance of Musculoskeletal.
Lofbo-ltss-001...Active Surveillance of Musculoskeletal.
|
|
10-2006
|
Merck Protocol 272-03
Merck Protocol 272-03
|
|
08-2006
|
Evaluate the Safety and Effic of Ritonavir in...HIV
Evaluate the Safety and Effic of Ritonavir in...HIV
|
|
07-2006
|
Ryan White Title IV Grant for Coordinated HIV Services
Ryan White Title IV Grant for Coordinated HIV Services
|
|
06-2006
|
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
|
|
12-2005
|
Glaxo: APV 2002
Glaxo: APV 2002
|
|
08-2005
|
Glaxo: Havrix
Glaxo: Havrix
|
|
07-2005
|
RYAN WHITE TITLE IV GRANT FOR COORDINATED HIV SERVICES and
RYAN WHITE TITLE IV GRANT FOR COORDINATED HIV SERVICES and
|
|
07-2005
|
ATN 021 Prevalence of Morphologic and Metabolic Abnormal
ATN 021 Prevalence of Morphologic and Metabolic Abnormal
|
|
06-2005
|
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
|
|
06-2005
|
AN OPN-LBL SINGAL-DOSE MUTI-CTR PHARMACOKINETIC SAFETY and
AN OPN-LBL SINGAL-DOSE MUTI-CTR PHARMACOKINETIC SAFETY and
|
|
06-2005
|
AN OPN-LBL SINGLE-DOSE MUTLI-CTR PHARMACOKINETIC SAFETY
AN OPN-LBL SINGLE-DOSE MUTLI-CTR PHARMACOKINETIC SAFETY
|
|
06-2005
|
A PHASE III, OBSERVER-BLINDED,..SAFETY...GSK BIOLOGICALS
A PHASE III, OBSERVER-BLINDED,..SAFETY...GSK BIOLOGICALS
|
|
03-2005
|
AN OPN-LBL, SINGLE-DOSE, MULT-CTR, PHARMACOKINETIC SAFET
AN OPN-LBL, SINGLE-DOSE, MULT-CTR, PHARMACOKINETIC SAFET
|
|
10-2004
|
ACTG 381 - ESTABLISHMENT AND MAINTENANCE OF LONG-TERM UN
ACTG 381 - ESTABLISHMENT AND MAINTENANCE OF LONG-TERM UN
|
|
07-2004
|
NORTHEAST FLORIDA PEDIATRIC AIDS PROGRAM/RAINBOW CENTER
NORTHEAST FLORIDA PEDIATRIC AIDS PROGRAM/RAINBOW CENTER
|
|
06-2004
|
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY IN
|
|
10-2003
|
AIDS CLINICAL TRIALS - P367- MEDICAL CHART ABSTRACTION O
AIDS CLINICAL TRIALS - P367- MEDICAL CHART ABSTRACTION O
|
|
10-2003
|
AIDS CLINICAL TRIALS - PROTOCOL P1013: PHASE I/II TRIAL
AIDS CLINICAL TRIALS - PROTOCOL P1013: PHASE I/II TRIAL
|
|
10-2003
|
P1008 - AN OBSERVATIONAL STUDY OF THE RATE OF OPPORTUNIS
P1008 - AN OBSERVATIONAL STUDY OF THE RATE OF OPPORTUNIS
|
|
08-2003
|
RYAN WHITE CARE ACT TITLE III PLANNING GRANT PROGRAM CFD
RYAN WHITE CARE ACT TITLE III PLANNING GRANT PROGRAM CFD
|
|
08-2003
|
P1021 - NIH HIV/AIDS CLINICAL TRIALS
P1021 - NIH HIV/AIDS CLINICAL TRIALS
|
|
06-2003
|
CLINICAL STUDIES OF THERAPIES FOR VIRUS INFECTIONS
CLINICAL STUDIES OF THERAPIES FOR VIRUS INFECTIONS
|
|
03-2003
|
P1013 - NIH HIV/AIDS CLINICAL TRIALS
P1013 - NIH HIV/AIDS CLINICAL TRIALS
|
|
02-2003
|
NIH HIV/AIDS CLINICAL TRIALS
NIH HIV/AIDS CLINICAL TRIALS
|
|
01-2003
|
NIH HIV/AIDS CLINICAL TRIAL - PACTG P1008
NIH HIV/AIDS CLINICAL TRIAL - PACTG P1008
|
|
01-2003
|
NIH HIV/AIDS CLINICAL TRIALS
NIH HIV/AIDS CLINICAL TRIALS
|
|
10-2002
|
AIDS CLINICAL TRIALS - STUDY 326
AIDS CLINICAL TRIALS - STUDY 326
|
|
10-2002
|
AIDS CLINICAL TRIALS (STUDY NO. 219C)
AIDS CLINICAL TRIALS (STUDY NO. 219C)
|
|
10-2002
|
AIDS CLINICAL TRIALS (STUDY NO. 247)
AIDS CLINICAL TRIALS (STUDY NO. 247)
|
|
10-2002
|
PROTOCOLS FOR AIDS CLINICAL TRIALS GROUP
PROTOCOLS FOR AIDS CLINICAL TRIALS GROUP
|
|
07-2002
|
3PN-LBL STDY OF A ONCE DAILY DOSE OF EMCITRABINE IN COMB
3PN-LBL STDY OF A ONCE DAILY DOSE OF EMCITRABINE IN COMB
|
|
09-2001
|
STUDY OF MKC 442 IN COMBINATION WITH NUCLEOSIDE REVERSE
STUDY OF MKC 442 IN COMBINATION WITH NUCLEOSIDE REVERSE
|
|
09-2001
|
AN OPEN LABEL, FIXED DOSE STUDY TO ASSESS THE EFFICACY,
AN OPEN LABEL, FIXED DOSE STUDY TO ASSESS THE EFFICACY,
|
|
07-2001
|
AN EVALUATION OF THE SAFETY AND PHARMACOKINETICS OF SING
AN EVALUATION OF THE SAFETY AND PHARMACOKINETICS OF SING
|
|
08-2000
|
A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF
A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF
|
|
06-2000
|
HIV DATA NETWORK
HIV DATA NETWORK
|
|
11-1999
|
STUDY OF MKC-442 COMBINED WITH STAVUDINE, DIDANOSINE and H
STUDY OF MKC-442 COMBINED WITH STAVUDINE, DIDANOSINE and H
|
